Abstract
28MO Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have